ENDRA Life Sciences (NDRA) Operating Expenses (2016 - 2026)

ENDRA Life Sciences has disclosed Operating Expenses across 11 years of filings, most recently posting $2.2 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 47.95% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $6.5 million (down 31.96% YoY), while the FY2025 annual figure was $5.8 million, down 46.72% from the prior year.
• Operating Expenses climbed to $2.2 million in Q1 2026, from $1.6 million in the prior quarter.
• Over the last five years, Operating Expenses for NDRA reached as high as $4.3 million in Q4 2024 and fell as low as $1.3 million in Q2 2025.
• The 5-year median for Operating Expenses is $2.8 million (2024), against an average of $2.5 million.
• Annual changes were most pronounced in 2024 — Operating Expenses jumped 194.75% — and 2025, when it slumped 62.25%.
• A 5-year view of Operating Expenses shows it stood at $3.3 million in 2022, then slumped by 56.0% to $1.5 million in 2023, then jumped by 194.75% to $4.3 million in 2024, then tumbled by 62.25% to $1.6 million in 2025, then surged by 34.01% to $2.2 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $2.2 million, $1.6 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.